Stem Cell Therapeutic and Research Reauthorization Act of 2025
Latest Action
Received in the Senate. Read twice. Placed on Senate Legislative Calendar under General Orders. Calendar No. 464.
Official Summary
Stem Cell Therapeutic and Research Reauthorization Act of 2025 This bill reauthorizes through FY2031 and revises programs that help patients receive transplants of bone marrow or umbilical cord blood from biologically unrelated donors. These programs are administered by the Health Resources and Services Administration (HRSA). The bill reauthorizes the C.W. Bill Young Cell Transplantation Program. This program supports transplantation of bone marrow and cord blood by increasing the quantities of donations, providing processes for matching and distributing donated materials to patients, and providing related information and research. Also, the bill reauthorizes and revises the National Cord Blood Inventory program, through which HRSA contracts with qualified cord blood banks to collect and maintain a supply of high-quality units for transplantation through the C.W. Bill Young Cell Transplantation Program. The bill amends the inventory program by (1) changing the inventory goal from 150,000 units to a sufficient supply as determined by HRSA, (2) requiring HRSA to manage the size and composition of the inventory to maximize clinical utility and efficiency, and (3) defining high quality cord blood unit to mean a unit meeting current industry standards and the requirements of the Food and Drug Administration.
GovScope Watchdog™
AI Government Intelligence™The Stem Cell Therapeutic and Research Reauthorization Act of 2025 reauthorizes and updates federal programs that facilitate bone marrow and umbilical cord blood transplants from unrelated donors. Administered by the Health Resources and Services Administration (HRSA), these programs include the C.W. Bill Young Cell Transplantation Program, which supports donation, matching, and distribution of transplant materials, and the National Cord Blood Inventory program, which contracts with cord blood banks to maintain a supply of high-quality units. The bill revises the inventory goal to be determined by HRSA based on clinical needs and defines quality standards aligned with FDA requirements. The reauthorization extends funding and program authority through fiscal year 2031.
This bill extends and updates federal support for bone marrow and cord blood transplantation programs to improve transplant availability and quality through 2031.
- Reauthorizes the C.W. Bill Young Cell Transplantation Program to support bone marrow and cord blood transplants from unrelated donors.
- Revises the National Cord Blood Inventory program by changing the inventory goal to a sufficient supply as determined by HRSA and requiring management to maximize clinical utility and efficiency.
- Defines 'high quality cord blood unit' based on current industry standards and FDA requirements.
- Extends program authorization and funding through fiscal year 2031.
- Programs are administered by HRSA, a federal agency within the Department of Health and Human Services.
['Patients requiring bone marrow or umbilical cord blood transplants', 'Health Resources and Services Administration (HRSA)', 'Qualified cord blood banks contracted by HRSA', 'Medical researchers and transplant clinicians involved in stem cell therapies']
['The bill leaves the inventory goal determination to HRSA discretion, which may affect predictability for cord blood banks and transplant centers.', 'Implementation depends on effective management by HRSA to balance inventory size and clinical utility, which may require ongoing oversight.', 'Costs associated with maintaining and expanding the inventory and transplantation programs through FY2031 may impact federal budgets.', 'The bill text does not specify new funding levels or oversight mechanisms, which could affect program accountability.']
This bill originates in the House during the 119th Congress and has been received and placed on the Senate Legislative Calendar. It continues a longstanding federal commitment to support stem cell transplantation programs, reflecting ongoing legislative efforts to maintain and improve access to life-saving transplant therapies. The bill updates program goals and definitions to align with current clinical and regulatory standards.
Hidden impact flags detected: 2
GovScope reviewed 2 policy-risk categories. Hover for a quick definition. Click detected flags for bill-specific details.
['Improved management of cord blood inventory may enhance transplant matching efficiency and patient outcomes.', 'Reauthorization through FY2031 provides program stability, potentially encouraging continued research and development in stem cell therapies.', 'Changes in inventory goals and quality definitions may influence cord blood bank operations and industry standards.']
Transparency considerations include the need for clear reporting on how HRSA determines the 'sufficient supply' inventory goal and manages inventory composition. Oversight mechanisms for funding levels and program performance are not detailed in the available summary, suggesting a need for monitoring to ensure accountability. The absence of full bill text limits comprehensive analysis of enforcement and funding provisions.
GovScope Intelligence Roadmap
Future bill intelligence will connect sponsors, committee referrals, related votes, campaign finance, disclosures, and stock trades into one legislative intelligence view.